Finding Suitable Clinical Endpoints for a Potential Treatment of a Rare Genetic Disease: the Case of ARID1B

[1]  G. Santen,et al.  Rare disease specialists and clinical pharmacologists unite: Increase collection of longitudinal data! , 2019, British journal of clinical pharmacology.

[2]  A. Bruyneel,et al.  The validity of two commercially-available sleep trackers and actigraphy for assessment of sleep parameters in obstructive sleep apnea patients , 2019, PloS one.

[3]  John A. Sweeney,et al.  Discovering translational biomarkers in neurodevelopmental disorders , 2018, Nature Reviews Drug Discovery.

[4]  E. Berry-Kravis,et al.  Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective , 2018, Brain sciences.

[5]  Golder N Wilson,et al.  The ARID1B spectrum in 143 patients: from nonsyndromic intellectual disability to Coffin–Siris syndrome , 2018, Genetics in Medicine.

[6]  S. Dravid,et al.  Arid1b haploinsufficiency disrupts cortical interneuron development and mouse behavior , 2017, Nature Neuroscience.

[7]  A. Reiss,et al.  Updated report on tools to measure outcomes of clinical trials in fragile X syndrome , 2017, Journal of Neurodevelopmental Disorders.

[8]  M. Bear,et al.  Arbaclofen in fragile X syndrome: results of phase 3 trials , 2017, Journal of Neurodevelopmental Disorders.

[9]  C. V. van Karnebeek,et al.  Treatment of Neurogenetic Developmental Conditions: From 2016 into the Future. , 2016, Pediatric neurology.

[10]  G. Tomlinson,et al.  Alternative designs for clinical trials in rare diseases , 2016, American journal of medical genetics. Part C, Seminars in medical genetics.

[11]  G. Groeneveld,et al.  Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery. , 2016, Drug discovery today. Technologies.

[12]  A. Blokland,et al.  The use of EEG parameters as predictors of drug effects on cognition. , 2015, European journal of pharmacology.

[13]  B. J. Wilkes,et al.  Oculomotor performance in children with high-functioning Autism Spectrum Disorders. , 2015, Research in developmental disabilities.

[14]  Abdulaziz Alghamdi.  Pediatric neurology. , 2020, Neurosciences.

[15]  J. Clayton-Smith,et al.  The ARID1B phenotype: What we have learned so far , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[16]  S. Lippé,et al.  Event-related potential alterations in fragile X syndrome , 2012, Front. Hum. Neurosci..

[17]  Christian Gilissen,et al.  Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome , 2012, Nature Genetics.

[18]  Tadashi Kaname,et al.  New from NPG , 2012, Nature Medicine.

[19]  B. O’Donnell,et al.  Steady state responses: electrophysiological assessment of sensory function in schizophrenia. , 2009, Schizophrenia bulletin.

[20]  M. Mustari,et al.  Signal Processing and Distribution in Cortical‐Brainstem Pathways for Smooth Pursuit Eye Movements , 2009, Annals of the New York Academy of Sciences.

[21]  G. O'driscoll,et al.  Smooth pursuit in schizophrenia: A meta-analytic review of research since 1993 , 2008, Brain and Cognition.

[22]  B. Clementz,et al.  Neurophysiology and neuroanatomy of reflexive and volitional saccades: Evidence from studies of humans , 2008, Brain and Cognition.

[23]  Jelle Jolles,et al.  Rey's verbal learning test: Normative data for 1855 healthy participants aged 24–81 years and the influence of age, sex, education, and mode of presentation , 2005, Journal of the International Neuropsychological Society.

[24]  R. Gieschke,et al.  Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state , 2005, Psychopharmacology.

[25]  A F Cohen,et al.  Biomarkers for the effects of benzodiazepines in healthy volunteers. , 2002, British journal of clinical pharmacology.

[26]  Mara L. Morr,et al.  Maturation of Mismatch Negativity in School‐Age Children , 2000, Ear and hearing.

[27]  T. Tombaugh,et al.  Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. , 1999, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[28]  E Plante,et al.  IQ variability in children with SLI: implications for use of cognitive referencing in determining SLI. , 1997, Journal of communication disorders.

[29]  H. Schoemaker,et al.  A comparison of the sensitivities of adaptive tracking, eye movement analysis, and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers , 1991, Clinical pharmacology and therapeutics.

[30]  J. Schuerger,et al.  The temporal stability of individually tested intelligence , 1989 .

[31]  M. Aman,et al.  The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. , 1985, American journal of mental deficiency.

[32]  R G Borland,et al.  Visual motor co-ordination and dynamic visual acuity. , 1984, British journal of clinical pharmacology.